Evidence map›Paper›PMID 40143865›Full record

ArticleFrontiers in microbiology2025

Cohort analysis of high-risk HPV infection in adult women in Dapeng New District, Shenzhen, Guangdong Province, China.

Weifeng Wei, Mi Zhang, Yiyuan Lin, Ziyin Li, Wenbo Luo, Weihua Zhao, Jing Zhuang, Weining Zhao, Zhixue Xu, Gaomin Li and 5 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Weifeng Wei *Shenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Mi Zhang *Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Yiyuan LinCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Ziyin LiCollege of Medicine, Shenzhen University, Shenzhen, China.
Wenbo LuoDapeng New District Center for Disease Control and Prevention, Shenzhen, Guangdong, China.
Weihua ZhaoShenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Jing ZhuangShenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Weining ZhaoCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Zhixue XuCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Gaomin LiCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Wenjing ZengShenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Liping HuangShenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Yan TanShenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Zhiying YuDapeng New District Center for Disease Control and Prevention, Shenzhen, Guangdong, China.
Guanglei LiCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cervical cancer is the fourth most commonly diagnosed malignancy among women globally, with HPV infection being the primary cause. Large-scale HPV screening is crucial for early detection, as appropriate intervention in HPV-positive individuals can significantly reduce cervical cancer incidence and mortality. Methods: Data were extracted from the Shenzhen Maternal and Child Health Management Information System, covering 18,667 HPV infection and cervical cancer screening instances among 15,850 women from January 1, 2020, to December 31, 2023. HPV prevalence and corresponding 95% confidence intervals (CIs) were calculated using SPSS (version 27.0). Results: From January 2020 to December 2023, the overall HPV infection rate was 12.39%, with a notably higher rate of 23.38% in women over 60 years. The hr-HPV infection rate was 12.99%, with HPV types 52, 58, 16, 51, and 68 being the most common. Among women with positive ThinPrep Cytologic Test (TCT) results, the hr-HPV infection rate was 53.37%. In women with positive cervical histopathology, the hr-HPV infection rate reached 95.95%. With increased HPV vaccination doses, the infection rates of HPV16, 18, 52, 58, 51, 31, 33, 45, 6, and 11 decreased among individuals under 30, but increased in those over 45. Discussion: These findings suggest that enhancing HPV vaccination coverage and cervical cancer screening, especially for women over 45, are effective strategies to reduce hr-HPV infection rates and cervical cancer incidence in this region.

Indexed as

cervical cancer screeninghuman papillomavirus (HPV)human papillomavirus vaccine vaccinationinfection rateShenzhen Dapeng New District

Identifiers

PMID40143865
PMCPMC11937043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.